Incidence, management and outcomes of the first cfr-mediated linezolid-resistant Staphylococcus epidermidis outbreak in a tertiary referral centre in the Republic of Ireland

Journal of Hospital Infection

Volumn 90, Issue 4, 2015, Pages 316-321

  O'Connor, C ^a,b   Powell, J ^a   Finnegan, C ^a   O'Gorman, A ^a   Barrett, S ^a   Hopkins, K L ^c   Pichon, B ^c   Hill, R ^c   Power, L ^a   Woodford, N ^c   Coffey, J C ^b   Kearns, A ^c   O'Connell, N H ^a,b   Dunne, C P ^b  

^a UNIVERSITY HOSPITAL LIMERICK   (Ireland)

^b UNIVERSITY OF LIMERICK   (Ireland)

^c PUBLIC HEALTH ENGLAND   (United Kingdom)

Author keywords

23S rRNA methyltransferase; First outbreak; Ireland; Multi resistance; Oxazolidinone resistance; Plasmid mediated; Staphylococci

Indexed keywords

CHLORHEXIDINE GLUCONATE; CIPROFLOXACIN; CLARITHROMYCIN; CLINDAMYCIN; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; ERYTHROMYCIN; FLUCLOXACILLIN; FUSIDIC ACID; GENTAMICIN; LINEZOLID; METICILLIN; MOXIFLOXACIN; OXACILLIN; PENICILLIN DERIVATIVE; PIPERACILLIN PLUS TAZOBACTAM; RIFAMPICIN; TEICOPLANIN; TETRACYCLINE; VANCOMYCIN; ANTIINFECTIVE AGENT; RNA 23S;

ADULT; AGED; ANTIBIOTIC RESISTANCE; ARTICLE; ASPIRATION PNEUMONIA; CFR GENE; CLINICAL ARTICLE; CLONE; EPIDEMIC; FEMALE; GENE; GENE CASSETTE; GENE MUTATION; GENOTYPE; HEALTH CARE MANAGEMENT; HUMAN; INCIDENCE; INFECTION PREVENTION; INTENSIVE CARE UNIT; IRELAND; LINEZOLID RESISTANT STAPHYLOCOCCUS EPIDERMIDIS; MALE; MIDDLE AGED; MULTILOCUS SEQUENCE TYPING; NONHUMAN; OUTCOME ASSESSMENT; PULSED FIELD GEL ELECTROPHORESIS; STAPHYLOCOCCUS EPIDERMIDIS; STAPHYLOCOCCUS INFECTION; TERTIARY CARE CENTER; VERY ELDERLY; CROSS INFECTION; DISEASE OUTBREAKS; DRUG EFFECTS; GENETICS; INFECTION CONTROL; ISOLATION AND PURIFICATION; MICROBIOLOGY; MULTIDRUG RESISTANCE; MUTATION; PROCEDURES; STAPHYLOCOCCAL INFECTIONS; TEACHING HOSPITAL; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; CROSS INFECTION; DISEASE OUTBREAKS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ELECTROPHORESIS, GEL, PULSED-FIELD; FEMALE; HOSPITALS, TEACHING; HUMANS; INCIDENCE; INFECTION CONTROL; IRELAND; LINEZOLID; MALE; MIDDLE AGED; MUTATION; RNA, RIBOSOMAL, 23S; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS EPIDERMIDIS; TREATMENT OUTCOME;

EID: 84937634874     PISSN: 01956701     EISSN: 15322939     Source Type: Journal    
DOI: 10.1016/j.jhin.2014.12.013     Document Type: Article

References (28)

1. Boak L.M., Rayner C.R., Grayson M.L., et al. Clinical population pharmacokinetics and toxicodynamics of linezolid. Antimicrob Agents Chemother 2014, 58:2334-2343.
2. Leach K.L., Brickner S.J., Noe M.C., Miller P.F. Linezolid, the first oxazolidinone antibacterial agent. Ann N Y Acad Sci 2011, 1222:49-54.
3. Jones R.N., Kohno S., Ono Y., Ross J.E., Yanagihara K. ZAAPS International Surveillance Program (2007) for linezolid resistance: results from 5591 Gram-positive clinical isolates in 23 countries. Diagn Microbiol Infect Dis 2009, 64:191-201.
4. Jones R.N., Fritsche T.R., Sader H.S., Ross J.E. LEADER surveillance program results for 2006: an activity and spectrum analysis of linezolid using clinical isolates from the United States (50 medical centers). Diagn Microbiol Infect Dis 2007, 59:309-317.
5. Ross J.E., Farrell D.J., Mendes R.E., Sader H.S., Jones R.N. Eight-year (2002-2009) summary of the linezolid (Zyvox(R) Annual Appraisal of Potency and Spectrum; ZAAPS) program in European countries. JChemother (Florence, Italy) 2011, 23:71-76.
6. Hong T., Li X., Wang J., Sloan C., Cicogna C. Sequential linezolid-resistant Staphylococcus epidermidis isolates with G2576T mutation. JClin Microbiol 2007, 45:3277-3280.
7. Wolter N., Smith A.M., Farrell D.J., et al. Novel mechanism of resistance to oxazolidinones, macrolides, and chloramphenicol in ribosomal protein L4 of the pneumococcus. Antimicrob Agents Chemother 2005, 49:3554-3557.
8. Mendes R.E., Deshpande L.M., Farrell D.J., Spanu T., Fadda G., Jones R.N. Assessment of linezolid resistance mechanisms among Staphylococcus epidermidis causing bacteraemia in Rome, Italy. JAntimicrob Chemother 2010, 65:2329-2335.
9. Shaw K.J., Barbachyn M.R. The oxazolidinones: past, present, and future. Ann N Y Acad Sci 2011, 1241:48-70.
10. Kehrenberg C., Aarestrup F.M., Schwarz S. IS21-558 insertion sequences are involved in the mobility of the multiresistance gene cfr. Antimicrob Agents Chemother 2007, 51:483-487.
11. LaMarre J., Mendes R.E., Szal T., Schwarz S., Jones R.N., Mankin A.S. The genetic environment of the cfr gene and the presence of other mechanisms account for the very high linezolid resistance of Staphylococcus epidermidis isolate 426-3147L. Antimicrob Agents Chemother 2013, 57:1173-1179.
12. Mendes R.E., Deshpande L., Rodriguez-Noriega E., Ross J.E., Jones R.N., Morfin-Otero R. First report of staphylococcal clinical isolates in Mexico with linezolid resistance caused by cfr: evidence of invivo cfr mobilization. JClin Microbiol 2010, 48:3041-3043.
13. Morales G., Picazo J.J., Baos E., et al. Resistance to linezolid is mediated by the cfr gene in the first report of an outbreak of linezolid-resistant Staphylococcus aureus. Clin Infect Dis 2010, 50:821-825.
14. Baos E., Candel F.J., Merino P., Pena I., Picazo J.J. Characterization and monitoring of linezolid-resistant clinical isolates of Staphylococcus epidermidis in an intensive care unit 4 years after an outbreak of infection by cfr-mediated linezolid-resistant Staphylococcus aureus. Diagnost Microbiol Infect Dis 2013, 76:325-329.
15. Diaz L., Kiratisin P., Mendes R.E., Panesso D., Singh K.V., Arias C.A. Transferable plasmid-mediated resistance to linezolid due to cfr in a human clinical isolate of Enterococcus faecalis. Antimicrob Agents Chemother 2012, 56:3917-3922.
16. Gu B., Kelesidis T., Tsiodras S., Hindler J., Humphries R.M. The emerging problem of linezolid-resistant staphylococcus. JAntimicrob Chemother 2013, 68:4-11.
17. O'Connor C., Fitzgibbon M., Powell J., et al. Acommentary on the role of molecular technology and automation in clinical diagnostics. Bioengineered 2014, 5:155-160.
18. Mendes R.E., Hogan P.A., Streit J.M., Jones R.N., Flamm R.K. Zyvox(R) Annual Appraisal of Potency and Spectrum (ZAAPS) program: report of linezolid activity over 9 years (2004-12). JAntimicrob Chemother 2014, 69:1582-1588.
19. Flamm R.K., Mendes R.E., Ross J.E., Sader H.S., Jones R.N. Linezolid surveillance results for the United States: LEADER surveillance program 2011. Antimicrob Agents Chemother 2013, 57:1077-1081.
20. Ellington M.J., Perry C., Ganner M., et al. Clinical and molecular epidemiology of ciprofloxacin-susceptible MRSA encoding PVL in England and Wales. Eur J Clin Microbiol Infect Dis 2009, 28:1113-1121.
21. Thomas J.C., Vargas M.R., Miragaia M., Peacock S.J., Archer G.L., Enright M.C. Improved multilocus sequence typing scheme for Staphylococcus epidermidis. JClin Microbiol 2007, 45:616-619.
22. Long K.S., Poehlsgaard J., Kehrenberg C., Schwarz S., Vester B. The Cfr rRNA methyltransferase confers resistance to phenicols, lincosamides, oxazolidinones, pleuromutilins, and streptogramin A antibiotics. Antimicrob Agents Chemother 2006, 50:2500-2505.
23. Schwarz S., Werckenthin C., Kehrenberg C. Identification of a plasmid-borne chloramphenicol-florfenicol resistance gene in Staphylococcus sciuri. Antimicrob Agents Chemother 2000, 44:2530-2533.
24. Toh S.M., Xiong L., Arias C.A., et al. Acquisition of a natural resistance gene renders a clinical strain of methicillin-resistant Staphylococcus aureus resistant to the synthetic antibiotic linezolid. Molec Microbiol 2007, 64:1506-1514.
25. Mendes R.E., Deshpande L.M., Castanheira M., DiPersio J., Saubolle M.A., Jones R.N. First report of cfr-mediated resistance to linezolid in human staphylococcal clinical isolates recovered in the United States. Antimicrob Agents Chemother 2008, 52:2244-2246.
26. Sierra J.M., Camoez M., Tubau F., et al. Low prevalence of Cfr-mediated linezolid resistance among methicillin-resistant Staphylococcus aureus in a Spanish hospital: case report on linezolid resistance acquired during linezolid therapy. PloS One 2013, 8:e59215.
27. Fessler A.T., Calvo N., Gutierrez N., et al. Cfr-mediated linezolid resistance in methicillin-resistant Staphylococcus aureus and Staphylococcus haemolyticus associated with clinical infections in humans: two case reports. JAntimicrob Chemother 2014, 69:268-270.
28. Sanchez Garcia M., de la Torre M.A., Morales G., et al. Clinical outbreak of linezolid-resistant Staphylococcus aureus in an intensive care unit. JAMA 2010, 303:2260-2264.